<DOC>
	<DOCNO>NCT00392470</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Drugs use chemotherapy , irinotecan , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving radiation therapy together irinotecan cetuximab surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase I trial study side effect best dose irinotecan give together cetuximab radiation therapy treat patient undergo surgery stage III stage IV rectal cancer .</brief_summary>
	<brief_title>Radiation Therapy , Irinotecan , Cetuximab Treating Patients Who Are Undergoing Surgery Stage III Stage IV Rectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity irinotecan hydrochloride cetuximab patient stage III IV rectal cancer undergo conformal intensity-modulated radiotherapy . Secondary - Determine rate pathologic response histological degree tumor regression patient treat regimen . - Determine complete resection rate ( R0 ) patient treat regimen . - Determine sphincter preservation rate patient treat regimen . - Determine 30-day postoperative complication rate patient treat regimen . - Determine local distant relapse rate site disease failure patient treat regimen . - Estimate predictive value fludeoxyglucose F 18 positron emission tomography/CT scan treatment response compare endoscopic ultrasonography ( EUS ) , CT scan , MRI patient treat regimen . - Determine late toxicity regimen patient . - Determine clinical ( radiological ) tumor response ( i.e. , MRI , CT scan , EUS ) patient treat regimen . OUTLINE : This dose-escalation study irinotecan hydrochloride . Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 follow irinotecan hydrochloride IV 30 minute day 1 , 8 , 15 , 22 , 29 . Patients also undergo conformal radiotherapy intensity-modulated radiotherapy day 1-5 5 week . Patients undergo radical surgery 3-4 week completion neoadjuvant therapy . Cohorts 3-6 patient receive escalate dos irinotecan hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow periodically least 5 year . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma rectum T34 and/or N+ ( stage IIIB , IIIC , IV disease ) Liver lung metastasis allow No recurrent disease PATIENT CHARACTERISTICS : WHO performance status 0 1 Hematologic , liver , renal function normal Considered fit chemotherapy , radiotherapy , surgery Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No symptomatic heart disease myocardial infarction past 6 month No chronic inflammatory bowel disease No malignant tumor past 5 year except completely surgically resect carcinoma cervix squamous cell carcinoma skin No concurrent malignant tumor PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy rectal cancer No prior radiotherapy pelvis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>